Last reviewed 2026-04-20 · How we verify

Hycanthon (HYCANTHONE)

Phase 2 active Small molecule

Hycanthon (generic name: HYCANTHONE) is a drug. It is currently in Phase 2 development.

Hycanthon works by stabilizing the DNA damage response to allow cells to repair DNA breaks.

Hycanthon (HYCANTHONE) is a small molecule modality targeting DNA-(apurinic or apyrimidinic site) lyase. Its mechanism involves stabilizing the DNA damage response, allowing cells to repair DNA breaks. However, specific details about its commercial status, approved indications, and pharmacokinetic properties are not available. Further research is needed to understand its potential therapeutic applications and safety profile. As a result, Hycanthon's clinical utility remains unclear.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 2 attrition -2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	HYCANTHONE
Target	DNA-(apurinic or apyrimidinic site) lyase
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

Imagine your DNA is a long, fragile ladder. When the ladder gets damaged, Hycanthon helps the cell's repair machinery to fix the breaks, preventing further damage and potential cancer. This process is crucial for maintaining the integrity of our genetic material.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Hycanthon CI brief — competitive landscape report
Hycanthon updates RSS · CI watch RSS

Frequently asked questions about Hycanthon

What is Hycanthon?

Hycanthon (HYCANTHONE) is a Small molecule drug.

How does Hycanthon work?

Hycanthon works by stabilizing the DNA damage response to allow cells to repair DNA breaks.

What is the generic name of Hycanthon?

HYCANTHONE is the generic (nonproprietary) name of Hycanthon.

What development phase is Hycanthon in?

Hycanthon is in Phase 2.

What does Hycanthon target?

Hycanthon targets DNA-(apurinic or apyrimidinic site) lyase.

Target: All drugs targeting DNA-(apurinic or apyrimidinic site) lyase
Therapeutic area: All drugs in Oncology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing